Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) does about 1.31M shares in volume on a normal day but saw 2535687 shares change hands in the recent trading day. The company now has a market cap of 205.09M USD. Its current market price is $28.00, marking an increase of 21.21% compared to the previous close of $23.10. The 52 week high reached by this stock is $672.00 whilst the lowest price level in 52 weeks is $6.76.
Tonix Pharmaceuticals Holding Corp (TNXP) has a 20-day trading average at $19.02 and the current price is -95.83% off the 52-week high compared with 314.20% distance from its 52-week low. The 50-day simple moving average of the closing price is $18.66 and its 200-day simple moving average is $22.04. If we look at the stock’s price movements over the week, volatility stands at 12.67%, which decreases to 9.51% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 76.80 to suggest the stock is overbought.
The consensus objective for the share price is $70.00, suggesting that the stock has a potential upside of 60.0% over the period.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
ROTH Capital upgraded the stock to “Buy” from Neutral on April 18, 2019 at a price target of $4. ROTH Capital upgraded its price target at $6.
The current price level is 47.23%, 50.03%, and 27.03% away from its SMA20, SMA50, and SMA200 respectively, with the TNXP price moving below the 50-day SMA on current market day. Tonix Pharmaceuticals Holding Corp (TNXP) stock is up 48.70% over the week and 76.54% over the past month. Its price is -15.10% year-to-date and -95.14% over the past year.
To reach the target analysts have set, the stock logically needs to grow 60.0 percent from here.
Outstanding shares total 7.32M with insiders holding 0.00% of the shares and institutional holders owning 4.22% of the company’s common stock. The company has a return on investment of -73.00% and return on equity of -91.44%. The beta has a value of 1.88. Price to book ratio is 1.07 and price to sales ratio is 20.43.
